Aptose Biosciences Files Q1 2025 10-Q
Ticker: APTOF · Form: 10-Q · Filed: May 8, 2025 · CIK: 882361
Sentiment: neutral
Topics: 10-Q, biotech, financials, equity-facility
TL;DR
**APTO Q1 10-Q FILED: Check financials, warrants, and equity facility details.**
AI Summary
Aptose Biosciences Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first quarter of 2025. Key financial instruments and events mentioned include Series B Warrants, a Committed Equity Facility, and share-based compensation awards.
Why It Matters
This filing provides investors with an update on Aptose Biosciences' financial health and operational status for the first quarter of 2025, impacting investment decisions.
Risk Assessment
Risk Level: medium — Biotech companies like Aptose Biosciences are inherently risky due to the nature of drug development and regulatory hurdles.
Key Numbers
- Q1 2025 — Reporting Period (First quarter financial and operational update)
Key Players & Entities
- Aptose Biosciences Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250508 (date) — Filing date
- LORUS THERAPEUTICS INC (company) — Former company name
- IMUTEC PHARMA INC (company) — Former company name
- Series B Warrants (financial_instrument) — Mentioned financial instrument
- Committed Equity Facility (financial_instrument) — Mentioned financial instrument
FAQ
What is the total cash and cash equivalents as of March 31, 2025?
The filing does not explicitly state the total cash and cash equivalents for March 31, 2025, but mentions 'us-gaap:BankTimeDepositsMember' as of that date.
When were the Series B Warrants issued or became effective?
The Series B Warrants are associated with a date of 2024-06-03.
What is the purpose of the Committed Equity Facility mentioned?
The filing mentions a 'CommittedEquityFacility' with 'InitialCommitmentSharesMember' dated 2023-05-2, suggesting it's a facility for raising capital through share issuance.
What types of share-based compensation awards are detailed?
The filing mentions 'OptionsWithThreeYearVestingMember' and 'OptionsWithFourYearVestingMember' for share-based compensation awards with vesting periods of three and four years, respectively.
What was the previous name of Aptose Biosciences Inc. before LORUS THERAPEUTICS INC?
Before being known as LORUS THERAPEUTICS INC, the company was named IMUTEC PHARMA INC.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Aptose Biosciences Inc. (APTOF).